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Abstract
Due to its constantly growing incidence, obesity is an increasingly serious social and medical 
problem. Available data on the use of novel oral anticoagulants in morbidly obese and obese 
patients are very limited. However, we tried to summarize the available knowledge on the use 
of anticoagulants in this subpopulation of patients in everyday clinical practice. Studies on the 
clinical use of anticoagulants provide a poor basis for any adjustment of doses in obese patients 
as compared to patients with normal body weight. In our opinion, further studies are required 
in this particular population. (Cardiol J 2016; 23, 1: 12–16)
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Introduction
Due to its constantly growing incidence, obe-
sity is an increasingly serious social and medical 
problem. It is estimated that by the year 2030, 
patients with obesity will have comprised more 
than 50% of the general population while more than 
10% will have been diagnosed with morbid obesity 
defined as body mass index (BMI) of above 40 kg/m2 
[1]. Limited data are available on the use of novel 
oral anticoagulants in morbidly obese patients. 
Incomplete data are available also with regard to 
the conventional anticoagulants such as low mo-
lecular weight heparins or vitamin K antagonists. 
Overweight and obese patients are usually either 
excluded from clinical trials or their participation 
in such trials is significantly limited.
Therefore, the use of medications in this 
patient group remains a significant therapeutic 
challenge. In addition, as shown by pharmacoki-
netic studies, certain pharmacokinetic parameters 
such as distribution volume, biological half-life and 
clearance can be significantly altered in obese pa-
tients [2]. As shown by these data, drug dosage in 
obese patients should depend on both the patient 
and the drug. In clinical practice, physicians may 
often find themselves lacking confidence with re-
gard to therapeutic decisions as they are uncertain 
whether the dose of the drug should be increased 
proportionally to the body weight or reduced so as 
to prevent adverse effects.
Thus, we believe that there is a need to sum-
marize the available knowledge on the use of 
anticoagulants in this subpopulation of patients in 
everyday clinical practice.
Low molecular weight heparins
The dosage of low molecular weight heparins 
depends on the patient’s weight; this includes 
also obese or morbidly obese patients. Safety and 
efficacy of such doses calculated in this manner 
were confirmed for individual heparin products: 
in patients with total body weight of up to 144 kg 
(BMI £ 48 kg/m2) for enoxaparin [3], patients with 
total body weight of up to 190 kg (BMI £ 58 kg/m2) 
for dalteparin [4], and patients with total body 
weight of up to 165 kg (BMI £ 61 kg/m2) for tin-
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zaparin [5, 6]. No increased incidence of hemor-
rhagic complications or recurrent venous throm-
boembolism was found in the RIETE registry for 
patients with total body weight of more than 100 kg 
(range 100–160 kg) treated with unfractionated 
or low molecular weight heparin [7]. In addition, 
negative correlation between total body weight 
and anti-Xa activity (R2 = 0.63) was demonstrated 
in obese patients in whom a fixed preventive dose 
of enoxaparin was recommended [8]. Similar cor-
relations were demonstrated for nadroparin [9]. As 
shown by these studies, higher prophylactic doses 
of low molecular weight heparins should be used 
in patients with obesity [10]. However, it seems 
justified to measure anti-Xa activity in extremely 
obese patients.
Moreover, it is worth noticing that the drug 
can induce thrombocytopenia (heparin-induced 
thrombocytopenia [HIT]), by an immune-mediated 
mechanism [11]. The risk of HIT is related to many 
factors, including obesity, performed surgery (re-
lease of cytokines during tissue injury), sex, age, 
duration of heparin exposure, characteristics of 
heparin molecule (unfractionated heparin [UFH], 
low molecular weight heparin [LMWH]), genetic 
predisposition. It is mediated by IgG antibod-
ies which bind to epitopes on PF4. Then these 
immune complexes cross-link Fcg receptors on 
platelets, monocytes, as well as endothelial cells. 
It results in intense platelet activation, releasing 
procoagulant rich microparticles, thus activating 
coagulation cascade and facilitating coagulation (by 
providing an anionic phospholipid membrane syn-
drome). Thus, HIT is most frequently associated 
with thromboembolic complications including deep 
vein thrombosis, pulmonary embolism, stroke, 
peripheral artery thrombosis, necrotizing lesions 
at the heparin injections site [11–13].
Importantly, the risk of HIT is higher after 
administration of UFH than LMWH to patients 
after surgery [11, 12].
Vitamin K antagonists
The effect of obesity on the use of warfarin re-
mains a largely unexamined and academic problem 
due to the possibilities to effectively monitor the ef-
ficacy of treatment. Routledge et al. [14] point out that 
the key factors affecting the pharmacokinetic prop-
erties of warfarin are age followed by body weight.
The study by Wallace et al. [15], including 
211 patients with various body weights, determined 
the percentage of patients achieving international 
normalized ratio (INR) values within the therapeu-
tic range before being discharged from hospital: the 
obtained ratios were 71.1% of patients with normal 
body weight as compared to 42.3% of patients with 
obesity and 38% of patients with morbid obesity. 
Compared to patients with normal body weight, 
obese patients, and particularly morbidly obese 
patients, required more time to achieve therapeutic 
INR values (6 days vs. 8 and 10 days, respectively). 
Additionally, compared to normal weight, obese 
and morbidly obese patients were reported to have 
a decreased initial response to warfarin.
Novel anticoagulants belong to two different 
classes of the inhibitors of factor X (apixaban, ri-
varoxaban, edoxaban) and the inhibitors of factor II, 
or thrombin (dabigatran) [16].
Dabigatran
Based on the available clinical data and phar-
macokinetic properties of the drug, no dose adjust-
ments are required with regard to the patient’s 
body weight (section 5.2 [17]); however, close 
clinical monitoring is recommended only in the 
case of patients with body weight of < 50 kg (sec-
tion 4.4 [17]).
Nevertheless, it should be noted that Breuer 
et al. [18], in their article published in NEJM, pre-
sent a case of a 48-year-old patient with morbid 
obesity (BMI 44.7 kg/m2) admitted to hospital due 
to an ischemic stroke during dabigatran treatment 
(150 mg bid). The peak concentration of dabigatran 
measured in the patient was as low as 50 ng/mL 
(4 h after administration, i.e. at the maximum ex-
pected concentration time), which was unambigu-
ously lower than 90% confidence interval (CI) in 
the group of patients with average body weight. 
However, the fact that the patient had received 
a proton pump inhibitor, which reduced the bio-
availability of the drug by 12.5%, should also be 
taken into account [19]. The authors of the case 
report concluded that the dose of the drug might 
have been insufficient for effective treatment of 
patients with morbid obesity. In their analysis of 
pharmacokinetic properties of dabigatran from 
RE-LY study data, Liesenfeld et al. [19] demon-
strated that obesity affects the drug distribution 
volume, increasing it by 0.77% per each kilogram 
of body weight above the median value (80 kg). At 
the same time, the authors pointed out that the 
body weight had no effect on the area under the 
concentration vs. time curve (AUCss). The authors 
concluded that no dosage changes are required 
depending on patient’s weight [19].
Lachant et al. [20] reported a patient with 
a history of bariatric surgery undergoing dabigatran 
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treatment (150 mg twice daily). According to the 
authors, anatomical changes due to surgery made 
it impossible to efficiently absorb the drug.
In their study including 1,826 obese patients 
(32.1% of the overall study population), Eriksson 
et al. [21] observed similar (statistically insignifi-
cant, 0.08% reduction) risk of adverse endpoints 
(venous thromboembolism, death due to venous 
thromboembolism, significant bleeding) in patients 
receiving dabigatran 220 mg once daily vs. enoxa-
parin in primary prevention in patients subjected to 
orthopedic surgeries. Of note are the significantly 
better results obtained with dabigatran 220 mg 
once daily vs. enoxaparin 40 mg once daily in pa-
tients with obesity (33% relative risk reduction) 
and patients with normal body weights (52% rela-
tive risk reduction).
Could an increased dosage of dabigatran pro-
vide better therapeutic effects in obese patients? 
According to the current summary of product 
characteristics, obesity is not an indication for 
increasing the dosage of the drug [17].
Rivaroxaban
According to the summary of product charac-
teristics, there is no need to modify the dosage for 
extreme body weights, including body weights of 
> 120 kg. Thus, obesity was not an indication for 
an increase in drug dosage [22].
Kubitza et al. [23] compared the safety profile, 
pharmacokinetics and pharmacodynamics of rivar-
oxaban in groups of patients with body weights of 
< 50 kg, 70–80 kg, and > 120 kg but < 150 kg. 
Slightly shorter elongations of prothrombin times 
were observed in patients with increased body 
weights. The increased body weight did not signifi-
cantly disturb the pharmacokinetics and pharmaco-
dynamics of the drug. This was most probably due 
to the low volume of distribution of rivaroxaban. 
According to the results of the study, no dose 
adjustments are required in patients with body 
weights of up to 150 kg.
Friedman et al. [24] compared the efficacy 
of anticoagulation treatment with rivaroxaban 
(occurrence of asymptomatic/symptomatic deep 
vein thrombosis, pulmonary embolism, bleedings 
and other adverse effects in orthopedic surgery 
patients with BMI > 40 kg/m2 and < 40 kg/m2 
[subanalysis of a group of 12,355 patients]). The 
authors observed no differences in the incidence 
rates of aforementioned disorders.
Mahlmann et al. [25] described a case of 
a morbidly obese patient after bariatric surgery in 
whom rivaroxaban was used due to the high risk 
of venous thromboembolism. Rivaroxaban levels 
were determined 3 h, 6 h, 12 h, and 24 h after 
administration to obtain a typical pharmacokinetic 
profile. The authors concluded that no adjustments 
of rivaroxaban treatment were required in a patient 
after bariatric surgery. Another clinical case report 
was published by Safouris et al. [26] who suggested 
a better pharmacokinetic profile of rivaroxaban as 
compared to dabigatran in an obese patient with 
no comorbid diabetes. However, it should be un-
derlined that rivaroxaban, similarly to dabigatran, 
is mostly absorbed in upper gastrointestinal tract 
including stomach and small intestinum, therefore 
gastrectomy or sleeve surgery can potentially af-
fect their absorption.
Edoxaban
Edoxaban is a direct and reversible inhibitor 
of factor Xa. Hokusai-VTE study compared the ef-
ficacy and safety of an enoxaparin/unfractionated 
heparin lead-in followed by edoxaban 60 mg once 
daily vs. standard of care (enoxaparin/unfraction-
ated heparin lead-in followed by warfarin) in the 
treatment of symptomatic venous thromboembo-
lism, with a primary efficacy outcome of recurrent 
symptomatic venous tromboembolism and a pri-
mary safety outcome of major or clinically relevant 
bleeding [27]. In this study including 611 (14.8%) 
patients with body mass > 100 kg in the group 
treated with edoxaban and 654 (15.9%) patients 
with body mass > 100 kg in the group treated with 
warfarin, similar effects in both relative efficacy 
and safety were observed [27].
According to the available data, there is no 
need to modify the dosage for extreme body 
weights, including body weights of > 100 kg. Thus, 
obesity was not an indication for an increase in drug 
dosage [27, 28].
Apixaban
According to the summary of product char-
acteristics (5.2. Pharmacodynamic properties 
[29]), body weight of > 120 kg was associat-
ed with the exposure to medicinal product be-
ing reduced by ca. 30%, while body weight of 
< 50 kg was associated with the exposure to 
medicinal product being increased by ca. 30% as 
compared to patients with body weights in the 
range of 65–85 kg [29]. Upreti et al. [30] deter-
mined both plasma and urine levels of apixaban, 
as well as measured anti-Xa activity following 
administration of a single 10 mg dose of apixaban 
to 54 healthy volunteers (18 subjects with body 
weights of £ 50 kg, 18 subjects with body weights 
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of 65–85 kg, and 19 subjects with body weights 
of ≥ 120 kg [120–175 kg] and BMI ≥ 30 kg/m2, 
indicative of obesity). Maximum blood levels of the 
drug and areas under the concentration vs. time 
curve (AUC(0,μ)) were found to be respectively 31% 
(90% CI 18–41%) and 23% (90% CI 9–35%) lower 
in obese patients. The time to maximum concentra-
tion of apixaban in the group of obese patients was 
similar to that in the reference group and amounted 
to 3.90 h (1.00–6.00). In conclusion, the authors do 
not recommend any adjustments of apixaban dose 
depending on body weight [30, 31]. In a clinical 
study, Pandit et al. [31] found that apixaban is more 
effective than low molecular weight heparin in 
obese patients (OR 0.54, p = 0.01) with the lower 
dose of dabigatran (150 mg) being less effective 
(OR 1.81, p = 0.02).
Conclusions
Studies on clinical use of anticoagulants pro-
vide no basis for any adjustment of doses in obese 
patients as compared to patients with normal body 
weight [10, 16]. In our opinion, however, further 
studies are required in this specific population. 
Therefore, an increased caution should be ex-
ercised when using these drugs, particularly in 
morbidly obese patients.
Importantly, data on the use of anticoagulants 
in patients after various types of bariatric surgery 
are based on individual case reports only, and there-
fore, special attention should be paid when using 
oral anticoagulants, particularly after surgeries 
interfering with food absorption, until appropriate 
guidelines are established. Since no methods of new 
oral anticoagulants monitoring are widely available, 
bariatric surgery may affect new oral anticoagulants 
absorption and clinical experience in this population 
is highly limited; so we prefer anticoagulation with 
INR adjusted vitamin K antagonists in this group.
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